Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date (Ascending) Status
16729-0243-30 16729-0243 Topotecan Topotecan 1.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Jan. 1, 2024 In Use
16729-0243-31 16729-0243 Topotecan Topotecan 1.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous July 8, 2020 In Use
16729-0276-03 16729-0276 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Feb. 28, 2014 In Use
16729-0276-05 16729-0276 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Feb. 28, 2014 In Use
16729-0276-11 16729-0276 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous March 14, 2014 In Use
16729-0276-38 16729-0276 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous March 14, 2014 In Use
16729-0276-67 16729-0276 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous March 14, 2014 In Use
16729-0276-68 16729-0276 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous March 25, 2014 In Use
24979-0715-04 24979-0715 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF Oral Dec. 1, 2022 In Use
24979-0715-44 24979-0715 Sorafenib Sorafenib 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF Oral Dec. 1, 2022 In Use

Found 10,000 results in 5 millisecondsExport these results